Nello Mainolfi Sells 80,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 80,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $113.51 on Friday. The business’s 50-day moving average price is $87.36 and its 200 day moving average price is $83.12. The firm has a market cap of $9.34 billion, a price-to-earnings ratio of -31.80 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period in the previous year, the company posted ($0.82) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 55.5% on a year-over-year basis. Equities analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Baker BROS. Advisors LP grew its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC raised its position in Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the period. Vanguard Group Inc. raised its position in Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Kymera Therapeutics by 9.4% during the fourth quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares in the last quarter.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Seeking Alpha upgraded Kymera Therapeutics to Buy, citing strong pipeline progress, a roughly $1.5 billion cash position, and accelerated timing for KT-621 Phase 2b topline data by year-end 2026. The article argues the oral STAT6 degrader could compete in a large atopic dermatitis market and challenge injectable therapies. Article Title
• Positive Sentiment: Another Seeking Alpha note said Kymera is building toward a key 2H 2026 inflection point, with KT-621’s Phase 2b readout seen as a major catalyst. The commentary also highlighted rapid enrollment, a strong balance sheet, and possible partnership upside. Article Title
• Neutral Sentiment: Analysts continue to rate KYMR favorably overall, with the consensus still at Moderate Buy and recent target increases from firms including Truist and Canaccord Genuity suggesting confidence in the company’s pipeline and long-term prospects.
• Negative Sentiment: Recent insider sales from CEO Nello Mainolfi, CFO Bruce N. Jacobs, and insider Noah Goodman may weigh on sentiment, as the transactions were sizable and follow additional selling earlier in the quarter. Article Title

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on KYMR shares. Truist Financial increased their price target on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a report on Monday. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective for the company. Bank of America upped their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 8th. Finally, Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.